The Effect of Corynanthine on Intraocular Pressure in Clinical Trials

Janet B. Serle, Steven M. Podos, Jacqueline S. Lustgarten, Charles Teitelbaum, Colette H. Severin

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

A single drop, dose-response, double-masked study of the effect of corynanthine, a selective α1 adrenergic antagonist, on intraocular pressure (IOP) was carried out in 10 symmetrically ocular hypertensive patients. Corynanthine 1 % had no significant pressure lowering effect. Topical application of a 2% solution significantly (P < 0.05) reduced IOP for at least eight hours; at five hours; mean IOP (±SEM) was 20.6 ± 2.0 mmHg and 26.0 ± 4.9 mmHg, comparing treated and control eyes, respectively. The 5% solution caused a significant (P ± 0.05) bilateral reduction in IOP, comparing treated and control eyes to baseline IOP respectively. Two percent corynanthine applied topically two or three times daily for one, two, or three weeks to seven patients with symmetrical ocular hypertension did not reduce IOP. Alpha adrenergic antagonists may have a role in the treatment of glaucoma.

Original languageEnglish
Pages (from-to)977-980
Number of pages4
JournalOphthalmology
Volume92
Issue number7
DOIs
StatePublished - 1985

Keywords

  • alpha adrenergic antagonist
  • corynanthine
  • intraocular pressure
  • ocular hypertension

Fingerprint

Dive into the research topics of 'The Effect of Corynanthine on Intraocular Pressure in Clinical Trials'. Together they form a unique fingerprint.

Cite this